Engene Therapeutics Inc (ENGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 10/31
| 10-2023 | 09-2023 | 07-2023 | 06-2023 | 04-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 81,521 | 86 | N/A | 269 | N/A |
| Marketable Securities | 76 | N/A | N/A | N/A | N/A |
| Receivables | 2,343 | N/A | N/A | N/A | N/A |
| TOTAL | $85,440 | $106 | $N/A | $310 | $N/A |
| Non-Current Assets | |||||
| PPE Net | 589 | N/A | N/A | N/A | N/A |
| Other Non-Current Assets | 930 | 138,840 | 0 | 135,786 | 0 |
| TOTAL | $1,519 | $138,840 | $N/A | $135,786 | $N/A |
| Total Assets | $86,959 | $138,945 | $N/A | $136,096 | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,156 | 49 | 0 | 49 | 0 |
| Accrued Expenses | 3,539 | 7,413 | N/A | 5,493 | N/A |
| TOTAL | $5,257 | $11,642 | $N/A | $8,007 | $N/A |
| Non-Current Liabilities | |||||
| Long Term Debt | 9,216 | N/A | N/A | N/A | N/A |
| Other Non-Current Liabilities | 0 | 138,840 | 0 | 135,786 | 0 |
| TOTAL | $9,216 | $142,567 | $N/A | $139,514 | $N/A |
| Total Liabilities | $14,473 | $154,209 | $N/A | $147,521 | $N/A |
| Shareholders' Equity | |||||
| Common Shares | 259,373 | 0 | N/A | 0 | N/A |
| Retained earnings | -199,588 | -15,264 | N/A | -11,425 | N/A |
| Other shareholders' equity | -1,016 | 0 | 0 | 0 | 0 |
| TOTAL | $72,486 | $-15,263 | $N/A | $-11,425 | $N/A |
| Total Liabilities And Equity | $86,959 | $138,945 | $0 | $136,096 | $0 |